Pll Jhannesson - Oculis Holding Chief Officer
| OCS Stock | 16.16 0.79 5.14% |
Executive
Pll Jhannesson is Chief Officer of Oculis Holding AG
| Age | 42 |
| Address | Bahnhofstrasse 7, Zug, Switzerland, 6300 |
| Phone | 41 41 711 9325 |
| Web | https://oculis.com |
Oculis Holding Management Efficiency
The company has Return on Asset of (0.3346) % which means that on every $100 spent on assets, it lost $0.3346. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6933) %, meaning that it generated no profit with money invested by stockholders. Oculis Holding's management efficiency ratios could be used to measure how well Oculis Holding manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.91 in 2024. Return On Capital Employed is likely to drop to -0.89 in 2024. At this time, Oculis Holding's Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 8.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 12.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Matteo MD | Cue Biopharma | 55 | |
| Anne DVM | Molecular Partners AG | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| David MBA | Inhibrx | N/A | |
| Bonne MBA | Inhibrx | 47 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Dr Esq | Enliven Therapeutics | 47 | |
| Carlos Bais | Inhibrx | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| MD MBA | Molecular Partners AG | N/A | |
| Helen MD | Enliven Therapeutics | 61 | |
| Charbel PharmD | Inhibrx | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
Management Performance
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.33 |
Oculis Holding AG Leadership Team
Elected by the shareholders, the Oculis Holding's board of directors comprises two types of representatives: Oculis Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oculis. The board's role is to monitor Oculis Holding's management team and ensure that shareholders' interests are well served. Oculis Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oculis Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, Chief Officer | ||
| Ramin MD, Chief Officer | ||
| Virginia Dean, Chief Officer | ||
| Gudrun Bachmann, Chief Officer | ||
| Rebecca Weil, Chief Officer | ||
| Bastian MD, Chief Officer | ||
| Pll Jhannesson, Chief Officer | ||
| MD MBA, CEO Director | ||
| Sylvia Cheung, Chief Officer | ||
| Weibo Ding, Global China | ||
| Bastian Dehmel, Chief Development | ||
| Joanne MD, Chief Officer | ||
| Snehal PharmD, President Development | ||
| Fang Li, Senior Affairs | ||
| MPH MD, Chief Officer |
Oculis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oculis Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (83.94) % | ||||
| Current Valuation | 560.24 M | ||||
| Shares Outstanding | 41.95 M | ||||
| Shares Owned By Insiders | 7.23 % | ||||
| Shares Owned By Institutions | 31.80 % | ||||
| Number Of Shares Shorted | 24.32 K | ||||
| Price To Book | 6.31 X | ||||
| Price To Sales | 780.91 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oculis Stock Analysis
When running Oculis Holding's price analysis, check to measure Oculis Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oculis Holding is operating at the current time. Most of Oculis Holding's value examination focuses on studying past and present price action to predict the probability of Oculis Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oculis Holding's price. Additionally, you may evaluate how the addition of Oculis Holding to your portfolios can decrease your overall portfolio volatility.